Revosimeline

Revosimeline
Clinical data
Drug class	Muscarinic acetylcholine receptor agonist
Identifiers
	IUPAC name ethyl (1S,5R)-3-(3-oxo-2,8-diazaspiro[4.5]decan-8-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate;
CAS Number	1810001-96-7;
PubChem CID	133082878;
ChemSpider	71115963;
UNII	9GHO88L89C;
Chemical and physical data
Formula	C18H29N3O3
Molar mass	335.448 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)N1[C@@H]2CC[C@H]1CC(C2)N3CCC4(CC3)CC(=O)NC4;
	InChI InChI=1S/C18H29N3O3/c1-2-24-17(23)21-13-3-4-14(21)10-15(9-13)20-7-5-18(6-8-20)11-16(22)19-12-18/h13-15H,2-12H2,1H3,(H,19,22)/t13-,14+,15?; Key:IXAHYSYEIHSUAG-YIONKMFJSA-N;

Revosimeline is a muscarinic acetylcholine receptor agonist which has not been marketed at this time.^[1]^[2]^[3] It is said to be an agonist of the muscarinic acetylcholine M₁ receptor.^[3] The drug appears to be structurally distinct from earlier muscarinic acetylcholine receptor agonists like milameline and xanomeline.^[4] Its INNTooltip International Nonproprietary Name was designated in 2018.^[5]

References

^ World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 102. Retrieved 21 October 2024. -meline cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer's disease) E.1.0.0 (USAN: cholinergic agonists (arecoline derivatives used in the treatment of Alzheimer's disease)) [...] alvameline (79), cevimeline (76), itameline (77), milameline (74), revosimeline (120), sabcomeline (76), tazomeline (77), xanomeline (70)
^ "Proposed INN: List 120: Revosimelinum" (PDF). WHO Drug Information. 32 (4): 674. 2018. p. 382 revosimelinum revosimeline [...] replace the mode of action by the following one [...] muscarinic receptor agonist [...]
^ ^a ^b "REVOSIMELINE". Inxight Drugs. National Center for Advancing Translational Sciences (NCATS). Retrieved 26 October 2024.
^ "Revosimeline". PubChem. U.S. National Library of Medicine. Retrieved 26 October 2024.
^ "Recommended INN: List 80: revosimelinum" (PDF). WHO Drug Information. 32 (3): 482. 2018.

[WHO2024-1] World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 102. Retrieved 21 October 2024. -meline cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer's disease) E.1.0.0 (USAN: cholinergic agonists (arecoline derivatives used in the treatment of Alzheimer's disease)) [...] alvameline (79), cevimeline (76), itameline (77), milameline (74), revosimeline (120), sabcomeline (76), tazomeline (77), xanomeline (70)

[WHO2018a-2] "Proposed INN: List 120: Revosimelinum" (PDF). WHO Drug Information. 32 (4): 674. 2018. p. 382 revosimelinum revosimeline [...] replace the mode of action by the following one [...] muscarinic receptor agonist [...]

[InxightDrugs-3] "REVOSIMELINE". Inxight Drugs. National Center for Advancing Translational Sciences (NCATS). Retrieved 26 October 2024.

[PubChem-4] "Revosimeline". PubChem. U.S. National Library of Medicine. Retrieved 26 October 2024.

[WHO2018b-5] "Recommended INN: List 80: revosimelinum" (PDF). WHO Drug Information. 32 (3): 482. 2018.

[1]

[2]

[3]

[4]

[5]